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We report a patient with neonatal meningitis caused by 
a CTX-M-1–producing Escherichia coli K1 strain. The inﬂ  u-
ence of CTX-M production on virulence was investigated 
in cell culture and a newborn mouse model of meningitis. 
CTX-M production had no inﬂ  uence on virulence but was a 
major factor in clinical outcome.
E
scherichia coli is the second most common cause 
of neonatal meningitis. Neonatal meningitis E.  coli 
(NMEC) belong mainly to phylogenetic group B2 and har-
bor numerous virulence factors (1).
Since the beginning of the 21st century, an explosive 
spread of CTX-M–type extended-spectrum β-lactamases 
(ESBLs) in E. coli has occurred (2). These enzymes con-
fer resistance to nearly all β-lactam antimicrobial drugs, 
including third-generation cephalosporins, the ﬁ  rst-line 
treatment for patients with serious E. coli infections. How-
ever, CTX-M–type ESBLs have been observed mainly in 
E. coli strains with few virulence factors or in strains caus-
ing minor infections (3–5). In addition, bacterial resistance 
to antimicrobial drugs is frequently reported as difﬁ  cult to 
reconcile with bacterial virulence (6). Highly pathogenic 
E. coli such as NMEC are therefore considered susceptible 
to antimicrobial drugs (7). We report a clinical case of neo-
natal meningitis caused by CTX-M–producing NMEC and 
the inﬂ  uence of CTX-M production on virulence. 
The Study
In April 2007, a 39-year-old pregnant woman with am-
niotic sac rupture was admitted to a hospital in Orleans, 
France, at 28 weeks and 4 days of gestation. Treatment 
was started with betamethasone (12 mg 1×/d) for fetal lung 
maturation and amoxicillin (1g 3×/d) for 4 days. Because of 
a high serum level of C-reactive protein, antimicrobial drug 
therapy was switched to amoxicillin with clavulanic acid 
(1g 3×/d) for 1 day. A cesarean delivery was performed at 
29 weeks and 2 days of gestation. A lumbar puncture sam-
ple of the low-weight (1,560 g) newborn female was tinged 
with blood. Cerebrospinal ﬂ  uid (CSF) protein and glucose 
values were 4.00 g/L and 3.5 mmol/L, respectively. Results 
of CSF Gram staining were negative.
The infant was admitted to the neonatal critical care 
unit and received amoxicillin (150 mg), cefotaxime (120 
mg), and netilmicin (8 mg) 2×/d for 2 days. Culture of pla-
centa, maternal and infant blood, and infant gastric ﬂ  uid 
yielded E. coli. The isolate was resistant to antimicrobial 
drugs, including third-generation cephalosporins. Imipen-
em/cilastatin (25 mg 4×/d) and amikacin (15 mg 2×/d) were 
given for 2 days. Treatment with imipenem/cilastatin was 
given for 15 days and then stopped because of the infant’s 
clinical improvement and return of C-reactive protein to 
the reference level. Similar drug treatment was adminis-
trated to the mother.
One week after drug treatment was discontinued, the 
infant showed signs of septicemia. A second lumbar punc-
ture sample had protein and glucose levels of 4.56 g/L and 
0.1 mmol/L, respectively, and a leukocyte count of 4,700 
cells/μL (54% polymorphonuclear cells). E. coli were iso-
lated from blood and CSF cultures and showed a resistance 
pattern identical to that of the previous isolate. Meningitis 
was a complication of the initial sepsis or a relapse of initial 
unapparent meningitis (8).
Treatment was started with imipenem/cilastatin (30 
mg 4×/d) for 25 days and amikacin (15 mg 2×/d) for 5 days. 
Because the infant had a seizure, phenobarbital (22.5 mg) 
and ciproﬂ  oxacin (15 mg 2×/d) were prescribed for 5 ad-
ditional days. Her condition gradually improved and blood 
and CSF values returned to reference levels. The infant was 
discharged from the hospital 1 month later and treatment 
with the anticonvulsant was discontinued. She showed 
normal psychomotor development at a regular follow-up 
pediatric visit.
E. coli strains isolated from the mother and infant 
were indistinguishable by enterobacterial repetitive in-
tergenic consensus sequence 2 PCR, random ampliﬁ  ed 
polymorphic DNA analysis, and typing with a MALDI 
BioTyper (Bruker Daltonique, Wissembourg, France) 
(9). Thus, the isolates corresponded to the same strain, 
designated Orl-1. PCR-based phylogenetic analysis and 
serotyping showed that the strain belonged to group B2 
and serotype O7:K1:H7, a major O antigen encountered 
worldwide in NMEC (1).
Resistance of the Orl-1 strain (MICs 128 μg/mL for 
cefotaxime and 8 μg/mL for ceftazidime) was caused by 
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the gene encoding CTX-M-1. This strain was also resis-
tant to tetracycline, trimethoprim, and sulfamethoxazole 
and susceptible to cefoxitin, imipenem, aminoglycosides, 
quinolones, chloramphenicol, and fosfomycin. It harbored 
the major E. coli genes associated with neonatal meningitis 
(Table 1) (1,10).
Plasmids from Orl-1 were used to transform E. coli 
K-12 DH5α. Three resistance proﬁ  les that enabled detec-
tion of 3 plasmids were obtained. On the basis of screening 
of plasmid transformants and Orl-1, most virulence factors 
genes were presumably chromosomally encoded. Three 
virulence factors (aer, iss, and a second copy of iroN) were 
mediated by a tetracycline-resistant, large (≈180 kb), con-
jugative plasmid (pOrl-1-Te). The 2 other plasmids were 
pOrl-1-CTX-M-1, the CTX-M-1–encoding large (≈150 
kb) conjugative plasmid carrying resistance to trimethop-
rim and sulfamethoxazole, and pOrl-1-TEM-1, a TEM–1-
encoding small (<40 kb) plasmid.
A derivative strain that did not harbor the 3 plasmids 
(Orl-c) was obtained by plasmid elimination with ethidium 
bromide. Orl-1, Orl-c, and E. coli DH5α harboring pOrl-1-
CTX-M-1 were tested for invasiveness in human brain mi-
crovascular endothelial cells (10) and in a newborn mouse 
(C57BL/6 wild-type) model of meningitis (R. Mittal et 
al., unpub. data) to investigate the inﬂ  uence of CTX-M-1 
production on virulence. E. coli strain E44, a rifampicin-
resistant mutant of archetypical NMEC K1 strain RS218, 
was used as a positive control (10).
Orl-1 and Orl-c strains exhibited 3.5× lower inva-
siveness than strain E44. However, their ability to invade 
human brain microvascular endothelial cells was 400× 
higher than that of strain DH5α–CTX-M1. In the mouse 
model, DH5α–CTX-M1 did not cause bacteremia or men-
ingitis. In contrast, Orl-1, Orl-c, and E44 induced menin-
gitis (prevalences of 100%, 84%, and 85%, respectively) 
(Table 2). 
The difference between Orl-1 and Orl-c in the mouse 
model may be explained by loss of plasmid pOrl-1-Te from 
Orl-c. Plasmid pOrl-1-Te is likely similar to pS88-related 
plasmids of NMEC because they share 3 virulence factor 
genes (iss, aer, and iroN) and are large and conjugative. 
These plasmids contribute to virulence of NMEC (11). 
Orl-1 and Orl-c showed similar behaviors, which suggest-
ed that the CTX-M-1–encoding plasmid pOrl-1-CTX-M-1 
does not alter virulence of the strain.
Mice with E44- and Orl-1–induced neonatal menin-
gitis were treated with the third-generation cephalosporin 
cefotaxime, as recommended for humans. Despite antimi-
crobial drug treatment, Orl-1, but not strain E44, caused 
meningitis, suggesting that drug resistance is a major factor 
in clinical outcomes.
Conclusions
Studies have reported emergence of E. coli as the pre-
dominant organisms responsible for sepsis at any gesta-
tional age and for increased rates of drug-resistant E. coli 
caused by intrapartum drug prophylaxis (12). Spread of 
ESBLs in E. coli and intrapartum exposure to antimicrobial 
drugs may favor emergence of NMEC strains resistant to 
third-generation cephalosporins.
Two other well-characterized E. coli K1 strains pro-
ducing ESBLs have been isolated from patients with neo-
natal meningitis in Algeria and France. The ESBL was 
identiﬁ  ed as CTX-M-15 in both patients, and 1 infection 
was lethal (13,14). Other putative ESBL-producing E. coli 
K1 have been recently isolated, especially in developing 
countries (15).
Emergence of ESBL-producing E. coli strains, which 
are frequently resistant to ﬂ  uoroquinolone (2), highlights 
the need for possible alternatives to third-generation ce-
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Table 2. Incidence of meningitis in a newborn mouse model by Escherichia coli strain, France* 
Bacterial strain  No. animals  Mean ± SD bacteremia, log CFU/mL blood  No. positive CSF cultures (% meningitis) 
E44  20  6.95 ± 0.6  17 (85)† 
Orl-1  16  6.75 ± 0.8  16 (100)† 
Orl-c  17  6.60 ± 0.5  14 (82)† 
DH5Į-CTX-M1  10  0.10 ± 0.1  0 
*CSF, cerebrospinal fluid. 
†p<0.005, significantly higher than the incidence of meningitis by DH5Į-CTX-M1 by Ȥ
2 test. 
Table 1. Virulence factors of Orl-1 Escherichia coli K1 strain, 
France
Integrative
elements* (1) Virulence genes  Present
PAI III536–like iroN Yes 
sfa/foc Yes 
GimA-like  ibeA (gimA4), ptnC (gimA1)Y e s  
PAI IIJ96–like hra Yes 
hlyC, cnf1 No
PAI ICFT073–like hlyC No
aer (iucC)Y e s  
HPI-like  fyuA, irp-2 Yes 
GimB-like  gimB Yes 
pks island†  clbA, clbK-J, clbP, clbQ Yes 





cdtB-I to -V No
*PAI, pathogenicity island; HPI, high-pathogenicity island. 
†Positive cytopathogen effect with transient infection of HeLa cells. phalosporins for treatment of patients with infected with 
NMEC. Carbapenems are usually recommended for treat-
ment of infections with ESBL-producing E. coli (2). How-
ever, this case report shows the role of treatment duration 
and the need for additional pharmacokinetic and safety 
studies in neonates and for adjunctive therapies (8).
This characterization of a CTX-M-1–producing NMEC 
strain highlights the emergence of CTX-M–type ESBL in 
highly virulent E. coli. Because of worldwide spread of 
CTX-Ms, caution should be exercised in the management 
of patients with NMEC, and ﬁ  rst-line treatment for neona-
tal meningitis may need to be reconsidered.
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